VISTAGEN THERAPEUTICS, INC. Proceeds from Notes Payable
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Proceeds from Notes Payable of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-08-14
- VISTAGEN THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2026-03-31 was $0.00.
- VISTAGEN THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2025-12-31 was $0.00.
- VISTAGEN THERAPEUTICS, INC. proceeds from notes payable for the quarter ending 2025-09-30 was $0.00.
- VISTAGEN THERAPEUTICS, INC. proceeds from notes payable for fiscal 2026 was $1.02M.
- VISTAGEN THERAPEUTICS, INC. proceeds from notes payable for fiscal 2025 was $0.00.
- VISTAGEN THERAPEUTICS, INC. proceeds from notes payable for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- VISTAGEN THERAPEUTICS, INC. proceeds from notes payable for fiscal 2021 was $224.40K.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $0.00 derived: sum of 3 quarters · filed 2026-08-14 | $0.00 derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-15 | $0.00 derived: sum of 2 quarters · filed 2026-06-15 | $0.00 derived: sum of 3 quarters · filed 2026-06-15 | $1.02M 10-K · filed 2026-06-15 |
| 2025-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-12 | $1.02M 10-Q · filed 2026-02-12 | $1.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $1.02M 10-Q · filed 2025-11-13 | $1.02M derived: sum of 3 quarters · filed 2026-08-14 | $1.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.02M 10-Q · filed 2026-08-14 | $1.02M derived: sum of 2 quarters · filed 2026-08-14 | $1.02M derived: sum of 3 quarters · filed 2026-08-14 | $1.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-15 | $0.00 derived: sum of 2 quarters · filed 2026-06-15 | $0.00 derived: sum of 3 quarters · filed 2026-06-15 | $0.00 10-K · filed 2026-06-15 |
| 2024-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | $0.00 derived: sum of 2 quarters · filed 2026-02-12 | $0.00 10-Q · filed 2026-02-12 | |
| 2024-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | |||
| 2022-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-23 | $0.00 10-K · filed 2022-06-23 | ||
| 2021-12-31 | $0.00 10-Q · filed 2022-02-10 | |||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 derived: sum of 2 quarters · filed 2022-06-23 | $0.00 derived: sum of 3 quarters · filed 2022-06-23 | $0.00 derived: sum of 4 quarters · filed 2022-06-23 |
| 2021-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-23 | $0.00 derived: sum of 2 quarters · filed 2022-06-23 | $0.00 derived: sum of 3 quarters · filed 2022-06-23 | $224.40K 10-K · filed 2022-06-23 |
| 2020-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-10 | $0.00 derived: sum of 2 quarters · filed 2022-02-10 | $224.40K 10-Q · filed 2022-02-10 | $224.40K derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-12 | $224.40K 10-Q · filed 2020-11-12 | $224.40K 10-Q · filed 2021-11-10 | $224.40K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-06-30 | $224.40K 10-Q · filed 2021-08-12 | $224.40K derived: sum of 2 quarters · filed 2021-08-12 | $224.40K derived: sum of 3 quarters · filed 2021-08-12 | $224.40K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-29 | $0.00 derived: sum of 2 quarters · filed 2021-06-29 | $0.00 derived: sum of 3 quarters · filed 2021-06-29 | $0.00 10-K · filed 2021-06-29 |
| 2019-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-02-11 | $0.00 derived: sum of 2 quarters · filed 2021-02-11 | $0.00 10-Q · filed 2021-02-11 | |
| 2019-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |